{"name":"AskGene Pharma, Inc.","slug":"askgene-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ASKG315","genericName":"ASKG315","slug":"askg315","indication":"Other","status":"phase_1"},{"name":"ASKG915","genericName":"ASKG915","slug":"askg915","indication":"Other","status":"phase_1"},{"name":"ASKG712","genericName":"ASKG712","slug":"askg712","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ASKB589","genericName":"ASKB589","slug":"askb589","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"ASKG315","genericName":"ASKG315","slug":"askg315","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASKG915","genericName":"ASKG915","slug":"askg915","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASKB589","genericName":"ASKB589","slug":"askb589","phase":"phase_3","mechanism":"ASKB589 is a small molecule inhibitor of the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ASKG712","genericName":"ASKG712","slug":"askg712","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFByZGhHdnRKdWp0OWl2MjNZOHhtVF85XzRJOFpoRUpnYnBXRDhKRk5qREZCam1QeEJmLXNjUzd6SmpXNl9pd294NHVVMFhjR2RfU2dvTVJVbU9DVjJhOGFMc3ByNnBoSm84S2RSX3BJOGtjNWlxMTRTU2Zn?oc=5","date":"2025-12-20","type":"trial","source":"acsjournals.onlinelibrary.wiley.com","summary":"Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials - acsjournals.onlinelibrary.wiley.com","headline":"Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer tri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPNnE1cDd0SWlqR29QRVdwSzliX0tKbTlJRklFVzJuM2Y5ZWtMTUtIcDJVRkdnWmV3eE94OHU4LTdvNmR0QXJkOTJ1NXBla0l2Y19rVmxTbXlHTWxqNFM5ay1FNkFRQWNyazFGNXRiZ2g3UEtFSzlERU5RSjhhOHdUTE13?oc=5","date":"2025-07-23","type":"pipeline","source":"Yahoo Finance","summary":"Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight - Yahoo Finance","headline":"Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNYXA4eHhNcHF3T21EYXNYa1hzVTFHZm5lUTcxRmxiTzJXR1ZWZ1Q1eV9POE1IWmRHZ2tZTVVUaW1iamRJTVZiUkpzekVReVJPSldYckQ0RDV6V1RDWERaNXplaldGWVRES25SejdYRFk3MkFJWldKNWhzNE9iVERveVllaXNrdGg3a1huNEhsUl9tRTl0cHFqcFpyYw?oc=5","date":"2024-11-07","type":"pipeline","source":"R&D World","summary":"Top 10 U.S. biopharma hubs of 2024: East Coast dominance continues - R&D World","headline":"Top 10 U.S. biopharma hubs of 2024: East Coast dominance continues - R&D World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNMnFmaEhDX3dMYk1zTEdiOS1pQU5EVWRKVlVGZDNqOVhvNHNhTWF0S1lZcEoxMGZ5Ymo5ZVk4OW1BemVYY1ZNWTRKbHFqcHJ6VTViN1JId185ZDNfbF81NkY0MVVLQ0YwbW5aQ0hMUXhuc3BIYlBHN1BRUGNBX3ZmVmc2SjdBYU5wOS0yUzlRNS1sWE1tRXBVbEFWaWpuc1pvZ1pTUEduUGNFYWV2NDNtaEhqUQ?oc=5","date":"2024-01-18","type":"pipeline","source":"OncLive","summary":"ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers - OncLive","headline":"ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQbzNMWWhHODNWMVdyRnV1TmFwQ0pJQzBEZ2NITEhnNks2OGhveVh5ZDhwZXdCN0xaMnBXbjFJTzktdkkxcngtRjdNTHhtXzVvZ0xWSWl2aGFhLVVqQko4VDMzT3dkQUlOR3RPZElQQXloZ1N5dTJlamJEYnhOY3FPU2JPV1I2NFhZRHc4U19pMnhLRlBqZllV?oc=5","date":"2023-10-04","type":"trial","source":"Oncology Pipeline","summary":"The second phase 3 Claudin18.2 asset belongs to Transcenta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"The second phase 3 Claudin18.2 asset belongs to Transcenta | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQMGZubU9mZk5Fc3B4VWU3Tk5mS3h6UzQ0UlNWUUY0aXZJbUFGX1I3dlFQaDZTNHl5NWhYRVhLcnVRNFBEN08zYUpzMDlLU2lrWnc0enJNOTJ3SGtJMkhBZkJYWUZMVFhEblRmbC14NWxTY2t2YlNWR0N3YTBoekR1d3MwOUdqdHVMblhVbEJZVW1PaGlFVmpGalpuUmVsak1SVUtpbV9QTzNUTkZHNXJDaGZZTnBtakM0TWFzejZGU3JXckd5azlHMEs5dGVVc1MzcFk2LVR4LXJpRVdJX0VwVkxB?oc=5","date":"2022-05-31","type":"trial","source":"Ophthalmology Times","summary":"AffaMed Therapeutics announces first patient dosed in the Phase 1 clinical trial of AM712 in retinal disease - Ophthalmology Times","headline":"AffaMed Therapeutics announces first patient dosed in the Phase 1 clinical trial of AM712 in retinal disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQN0JBZmNBd2hMVjV1TDRHYlRyN1daM1BGZmtJQ2tHYzBKaWhEUXJKNWJMX0x2Mlo2a2pFd282T0VCNnRtSklEbWNrNkM4ZU1DRGg3UDVKNFhqVVQ4WFo2ZWIyMVVmamI4YzIyYXV2aDdzcTZzTTVrYTVuNlBCaFdNSA?oc=5","date":"2022-05-09","type":"pipeline","source":"BioSpace","summary":"The Rise and Expansion of Cytokine-based Therapy - BioSpace","headline":"The Rise and Expansion of Cytokine-based Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPWERPd0ltWWl5M0ZiVFdvV1Y4MHV5cFh4SmtsdnRON3VJQ1BKSFVHY1RpSjlGdTVteUlfX2p3WUxCNExIaU1TYmozMjg3bVN3UHd1dGQ0OE1wWXRqTUZfMmN2SWd6NWo5TEdGZWF6eEZHakg4eDlqU2ZvWHRTOG5TRXlNMGtBM0FHRnlZYlZaOXJmdXc3c2VDc1BSb1FRR1Y5OW5qNDNoX3EybW5JbkpiWDNxaXROQQ?oc=5","date":"2022-02-15","type":"regulatory","source":"Ophthalmology Times","summary":"AffaMed gets FDA IND clearance for AM712 to treat retinal vascular diseases - Ophthalmology Times","headline":"AffaMed gets FDA IND clearance for AM712 to treat retinal vascular diseases","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}